নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 5.11mg equivalent to 5 mg tacrolimus - capsule - 5 mg - active: tacrolimus monohydrate 5.11mg equivalent to 5 mg tacrolimus excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate opaque orange g3ics000767 - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidneys) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 0.767mg equivalent to 0.75mg tacrolimus - capsule - 0.75 mg - active: tacrolimus monohydrate 0.767mg equivalent to 0.75mg tacrolimus excipient: brilliant blue fcf   croscarmellose sodium ethanol gelatin   hypromellose iron oxide yellow   lactose monohydrate magnesium stearate titanium dioxide   - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - tacrolimus monohydrate 2.044mg equivalent to 0.2mg tacrolimus - capsule - 2 mg - active: tacrolimus monohydrate 2.044mg equivalent to 0.2mg tacrolimus excipient: brilliant blue fcf   croscarmellose sodium ethanol gelatin   hypromellose iron oxide red   iron oxide yellow   lactose monohydrate magnesium stearate titanium dioxide   - primary immunosuppression in liver, kidney, pancreas, kidney-pancreas, lung or heart allograft recipients and rescue use in liver, kidney or other solid organ (heart, lung, pancreas or kidney-pancreas) transplantation, that has either failed conventional immunosuppressive agents, or where such agents are producing intolerable side effects.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ticagrelor 60mg - film coated tablet - 60 mg - active: ticagrelor 60mg excipient: calcium hydrogen phosphate dihydrate maize starch mannitol opadry pink 88a240025 purified talc purified water sodium stearyl fumarate starch - co-administered with acetylsalicylic acid (aspirin), this product is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) " in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). " in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - ticagrelor 90mg - film coated tablet - 90 mg - active: ticagrelor 90mg excipient: calcium hydrogen phosphate dihydrate maize starch mannitol opadry yellow 88a220017 purified talc purified water sodium stearyl fumarate starch - co-administered with acetylsalicylic acid (aspirin), this product is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) " in patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg). " in patients with a history of myocardial infarction (mi occurred at least one year ago) and a high risk of developing an atherothrombotic event.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - dimethyl fumarate 120mg - modified release capsule - 120 mg - active: dimethyl fumarate 120mg excipient: brilliant blue fcf colloidal silicon dioxide   croscarmellose sodium gelatin methacrylic acid – methyl methacrylate copolymer (1:1) glycerol monostearate 40-55 ink iron oxide yellow isopropyl alcohol methacrylic acid - ethyl acrylate copolymer polysorbate 80 purified talc purified water sodium stearyl fumarate titanium dioxide triethyl citrate - indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay progression of disability.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml;   - concentrate for injection - 10 mg/ml - active: gemcitabine hydrochloride 11.39 mg/ml equivalent to gemcitabine 10 mg/ml   excipient: sodium acetate trihydrate sodium hydroxide water for injection - non-small cell lung cancer: gemcitabine ebewe, alone or in combination with cisplatin, is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - cefuroxime axetil 300.72mg equivalent to 250 mg cefuroxime - film coated tablet - 250 mg - active: cefuroxime axetil 300.72mg equivalent to 250 mg cefuroxime excipient: colloidal silicon dioxide croscarmellose sodium hydrogenated vegetable oil hypromellose methyl hydroxybenzoate microcrystalline cellulose opaspray white m-1-7120 propyl hydroxybenzoate propylene glycol sodium laurilsulfate - cefuroxime axetil is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most beta-lactamases and is active against a wide range of gram-positive and gram-negative organisms. zinnat is indicated in adults and children aged two years or older for the treatment of infections caused by sensitive bacteria. susceptibility to cefuroxime axetil will vary with geography and time, and it should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - epoetin alfa 16.8 µg/ml - solution for injection - 16.8 mcg/ml - active: epoetin alfa 16.8 µg/ml excipient: dibasic sodium phosphate dihydrate glycine hydrochloric acid monobasic sodium phosphate dihydrate nitrogen polysorbate 80 sodium chloride sodium hydroxide water for injection - binocrit is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.

নিউ জিলণ্ড - ইংরেজি - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - epoetin alfa 336 µg/ml - solution for injection - 336 mcg/ml - active: epoetin alfa 336 µg/ml excipient: dibasic sodium phosphate dihydrate glycine hydrochloric acid monobasic sodium phosphate dihydrate nitrogen polysorbate 80 sodium chloride sodium hydroxide water for injection - binocrit is indicated for: · the treatment of severe anaemia of renal origin accompanied by clinical symptoms in patients with renal insufficiency not yet undergoing dialysis · anaemia associated with chronic renal failure in paediatric and adult patients on dialysis · anaemia in patients with non-myeloid malignancies where anaemia is due to the effect of concomitantly administered chemotherapy · adult patients with mild-to-moderate anaemia (haemoglobin > 100 to < 130 g/l) scheduled for elective surgery with an expected moderate blood loss (2-4 units or 900 to 1800 ml) to reduce exposure to allogeneic blood transfusion and to facilitate erythropoietic recovery · to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adult patients undergoing major surgery who are not expected to pre-deposit their complete peri-operative blood needs.